PTPRZ1在口腔黏膜下纤维性变癌变中的表达及临床意义

doi:10.19439/j.sjos.2017.02.015

上海口腔医学 ›› 2017, Vol. 26 ›› Issue (2): 198-203.doi: 10.19439/j.sjos.2017.02.015

PTPRZ1在口腔黏膜下纤维性变癌变中的表达及临床意义

朱蓉¹, 翦新春^1,2, 刘德裕¹, 周超², 王媛¹

1.中南大学湘雅医学院附属海口医院口腔颌面外科,海南海口 570208;
2.中南大学湘雅医院口腔颌面外科,湖南长沙 410008

收稿日期:2016-06-12 修回日期:2016-09-18 出版日期:2017-04-25 发布日期:2017-05-04
通讯作者: 翦新春,E-mail:jianxinchun@hotmail.com
作者简介:朱蓉（1989-）,女,硕士,住院医师,E-mail:752904290@qq.com
基金资助:
国家自然科学基金(81260166）

Expression of PTPRZ1 in oral squamous cell carcinoma originated from oral submucous fibrosis and its clinical significance

ZHU Rong¹, JIAN Xin-chun^1,2, LIU De-yu¹, ZHOU Chao², WANG Yuan¹

1.Department of Oral and Maxillofacial Surgery, Affiliated Haikou Hospital of Xiangya Medical College. Haikou 570208, Hainan Province;
2. Department of Oral and Maxillofacial Surgery, Xiangya Hospital, Central South University. Changsha 410008, Hunan Province, China

Received:2016-06-12 Revised:2016-09-18 Online:2017-04-25 Published:2017-05-04

摘要/Abstract

摘要： 目的: 研究蛋白酪氨酸磷酸酶Z1型受体(PTPRZ1)蛋白在口腔黏膜下纤维性病变（OSF）癌变中的表达及分布特征,探讨其在OSF癌变发生、发展过程中的作用及临床意义。方法: 利用免疫组织化学（immunohistochemistry,IHC）及蛋白印迹技术（Western blot, WB）检测36例OSF癌变患者、23例非OSF癌变鳞癌患者及21例身体健康者颊黏膜组织中PTPRZ1蛋白分布及表达差异。采用SPSS 21.0软件包对数据进行统计学分析。结果: 免疫组织化学果显示,PTPRZ1蛋白在OSF癌变组的颊黏膜中呈阳性表达,阳性表达率为72.22%;在非OSF癌变的颊黏膜鳞癌组织中呈弱阳性表达,表达率为43.47%;在正常颊黏膜组织中呈阴性表达。PTPRZ1蛋白在OSF癌变组及非OSF癌变组中的表达显著高于正常对照组（P<0.01）;OSF癌变组显著高于非OSF癌变的口腔癌组（P<0.05）。Western 印迹结果显示,PTPRZ1在正常组织中不表达,在非OSF癌变的口腔鳞癌中微量表达,在OSF癌变组中显著表达。PTPRZ1与一般临床资料相关性分析发现,PTPRZ1与复发及转移呈显著正相关性（r_k=0.642,P<0.01;r_k=0.656,P<0.01）。结论: PTPRZ1在OSF癌变的发生、发展及侵袭、转移过程中发挥重要作用,可作为早期诊断分子标志物及治疗的靶基因。

关键词: 酪氨酸蛋白激酶Z1型受体, 口腔黏膜下纤维性变, 口腔鳞癌

Abstract: PURPOSES: This study was aimed to detect the expression of PTPRZ1 in oral squamous cell carcinoma (OSCC) originated from oral submucous fibrosis (OSF), and discuss its role in the development and progression of OSCC originating from OSF as well as its clinical significance. METHODS: Immunohistochemisty (IHC) and Western blot (WB) for the expression and distribution of PTPRZ1 were carried out in 36 cases of OSF transforming into OSCC, 23 cases of OSCC and 21 cases of healthy controls. The data were analyzed by Chi-square test using SPSS 21.0 software package. RESULTS: IHC results demonstrated that the expression of PTPRZ1 in OSCC originated from the OSF was strongly positive and the rate of positive expression was 72.22%; expression of PTPRZ1 in OSCC was weakly positive, the positive rate was 43.47%; and the expression of PTPRZ1 in healthy controls was negative. The rate of PTPRZ1 positive expression was significantly higher in OSCC originated from OSF and OSCC with non-OSF than that of the healthy controls (P<0.01). The positive expression rate of OSCC originated from OSF was significantly higher than that of OSCC with non-OSF (P<0.05).WB results showed the expression of PTPRZ1 was weak in the healthy controls and in OSCC with non-OSF, but strong in OSCC originated from OSF. Correlation analysis between PTPRZ1 and clinical data showed PTPRZ1 was correlated with recurrence and metastasis positively (r_k=0.642, P<0.05; r_k =0.656, P<0.05). CONCLUSIONS: Differential expression of PTPRZ1 in OSCC originating from OSF and OSCC with non-OSF was significant. PTPRZ1, which plays an important role in the processes of development, invasion and metastasis of OSCC originated from OSF, can be used as a molecular marker for early diagnosis and targeted gene for treatment of OSCC originating from OSF.

Key words: Protein tyrosine phosphatase receptor type Z1, Oral submucous fibrosis, Oral squamous cell carcinoma

中图分类号:

R739.8

朱蓉, 翦新春, 刘德裕, 周超, 王媛. PTPRZ1在口腔黏膜下纤维性变癌变中的表达及临床意义[J]. 上海口腔医学, 2017, 26(2): 198-203.

ZHU Rong, JIAN Xin-chun, LIU De-yu, ZHOU Chao, WANG Yuan. Expression of PTPRZ1 in oral squamous cell carcinoma originated from oral submucous fibrosis and its clinical significance[J]. Shanghai Journal of Stomatology, 2017, 26(2): 198-203.

参考文献

[1] 吴狄, 邓祥, 王坤, 等. 蛋白酪氨酸磷酸酶(PTPs)及其抑制剂的研究进展 [J]. 广州化工, 2012,40(9): 11-12.
[2] Labbé DP, Hardy S, Tremblay ML. Protein tyrosine phosphatases in cancer: friends and foes! [J]. Prog Mol Biol Transl Sci, 2012, 106: 253-306.
[3] Nikolaienko RM, Agyekum B, Bouyain S. Receptor protein tyrosine phosphatases and cancer: new insights from structural biology [J]. Cell Adh Migr, 2012, 6(4): 356-364.
[4] Ostman A, Hellberg C, Böhmer FD. Protein-tyrosine phosphatases and cancer[J]. Nat Rev Cancer, 2006, 6(4): 307-320.
[5] Hunter T. Signaling-2000 and beyond[J]. Cell, 2000, 100(1): 113-127.
[6] Makinoshima H, Ishii G, Kojima M, et al. PTPRZ1 regulates calmodulin phosphorylation and tumor progression in small-cell lung carcinoma [J]. BMC Cancer, 2012, 12: 537.
[7] Yi T, Lindner D. The role and target potential of protein tyrosine phosphatases in cancer[J]. Curr Oncol Rep, 2008, 10(2):114-121.
[8] Perez-Pinera P, Zhang W, Chang Y, et al. Anaplastic lymphoma kinase is activated through the pleiotrophin/receptor protein-tyrosine phosphatase beta/zeta signaling pathway: an alternative mechanism of receptor tyrosine kinase activation [J]. J Biol Chem, 2007, 282(39): 28683-28690.
[9] Wu CW, Kao HL, Li AF, et al. Protein tyrosine-phosphatase expression profiling in gastric cancer tissues[J]. Cancer Lett, 2006, 242(1): 95-103.
[10] 翦新春, 沈子华, 刘蜀凡. 口腔黏膜下纤维性变(附2例报告) [J]. 临床口腔医学杂志, 1985, 1(1): 12-13.
[11] Paymaster JC. Cancer of the buccal mucosa. A clinical study of 650 cases in Indian patients [J]. Cancer, 1956, 9(3): 431-435.
[12] Murti PR, Bhonsle RB, Pindborg JJ, et al. Malignant transformation rate in oral submucous fibrosis over a 17-year period[J]. Community Dent Oral Epidemiol, 1985, 13(6): 340-341.
[13] IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Betel-quid and areca-nut chewing and some areca-nut derived nitrosamines [J]. IARC Monogr Eval Carcinog Risks Hum, 2004, 85: 1-334.
[14] Garzino-Demo P, Dell'Acqua A, Dalmasso P, et al. Clinicopathological parameters and outcome of 245 patients operated for oral squamous cell carcinoma [J]. J Craniomaxillofac Surg, 2006, 34(6): 344-350.
[15] 郭峰. OSF癌变侵袭转移的临床研究及其与Wnt途径异常激活关系的初步研究[D]. 长沙: 中南大学, 2009.
[16] Song JJ, Liu J, Tolia NH, et al. The crystal structure of the Argonaute2 PAZ domain reveals an RNA binding motif in RNAi effector complexes [J]. Nat Struct Biol, 2003, 10(12): 1026-1032.
[17] 史一搏, 赵涵芳. 蛋白酪氨酸磷酸酶家族及其生理作用 [J]. 生命的化学, 2007, 27(4): 312-314.
[18] Shitara K, Yamada H, Watanabe K, et al. Brain-specific receptor-type protein-tyrosine phosphatase RPTP beta is a chondroitin sulfate proteoglycan in vivo [J]. J Biol Chem, 1994, 269(31): 20189-20193.
[19] Kadomatsu K, Muramatsu T. Midkine and pleiotrophin in neural development and cancer [J]. Cancer Lett, 2004, 204(2): 127-143.
[20] Liu YT, Shang D, Akatsuka S, et al. Chronic oxidative stress causes amplification and overexpression of ptprz1 protein tyrosine phosphatase to activate beta-catenin pathway[J]. Am J Pathol, 2007, 171(6): 1978-1988.
[21] Tamura H, Fukada M, Fujikawa A, et al. Protein tyrosine phosphatase receptor type Z is involved in hippocampus-dependent memory formation through dephosphorylation at Y1105 on p190 RhoGAP [J]. Neurosci Lett, 2006, 399(1-2): 33-38.
[22] Pariser H, Perez-Pinera P, Ezquerra L, et al. Pleiotrophin stimulates tyrosine phosphorylation of beta-adducin through inactivation of the transmembrane receptor protein tyrosine phosphatase beta/zeta [J]. Biochem Biophys Res Commun, 2005, 335(1): 232-239.
[23] Pariser H, Ezquerra L, Herradon G, et al. Fyn is a downstream target of the pleiotrophin/receptor protein tyrosine phosphatase beta/zeta-signaling pathway: regulation of tyrosine phosphorylation of Fyn by pleiotrophin [J]. Biochem Biophys Res Commun, 2005, 332(3): 664-669.
[24] Meng K, Rodriguez-Pena A, Dimitrov T, et al. Pleiotrophin signals increased tyrosine phosphorylation of beta beta-catenin through inactivation of the intrinsic catalytic activity of the receptor-type protein tyrosine phosphatase beta/zeta [J]. Proc Natl Acad Sci USA, 2000, 97(6): 2603-2608.
[25] Benaim G, Villalobo A. Phosphorylation of calmodulin. Functional implications[J]. Eur J Biochem, 2002, 269(15): 3619-3631.
[26] Corti C, Leclerc LE, Quadroni M, et al. Tyrosine phosphorylation modulates the interaction of calmodulin with its target proteins [J]. Eur J Biochem, 1999, 262(3): 790-802.
[27] Williams EL, Djamgoz MB. Nitric oxide and metastatic cell behaviour [J]. Bioessays, 2005, 27(12): 1228-1238.
[28] Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression [J]. Nat Rev Cancer, 2006, 6(7): 521-534.
[29] Eyler CE, Wu Q, Yan K, et al. Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2 [J]. Cell, 2011, 146(1): 53-66.
[30] Wang V, Davis DA, Veeranna RP, et al. Characterization of the activation of protein tyrosine phosphatase, receptor-type, Z polypeptide 1 (PTPRZ1) by hypoxia inducible factor-2 alpha [J]. PLoS One, 2010, 5(3): e9641.
[31] Jeong HC, Kim GI, Cho SH, et al. Proteomic analysis of human small cell lung cancer tissues: up-regulation of coactosin-like protein-1 [J]. J Proteome Res, 2011, 10(1): 269-276.

PTPRZ1在口腔黏膜下纤维性变癌变中的表达及临床意义

Expression of PTPRZ1 in oral squamous cell carcinoma originated from oral submucous fibrosis and its clinical significance

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	董淋升, 唐进, 程维, 冉婧璇, 刘兆博, 李雅冬. IL-6和β-catenin在口腔鳞癌中的表达及预后价值[J]. 上海口腔医学, 2023, 32(3): 280-286.
[2]	胡小媛, 王宁, 张晓野, 杨茜, 高菲, 王成勤, 尚伟, 项锋钢, 冯元勇. Chemerin对口腔鳞癌中性粒细胞浸润的影响及机制探讨[J]. 上海口腔医学, 2023, 32(2): 158-165.
[3]	郭梦瑶, 李凯玉, 聂敏海, 刘旭倩. 上调Decorin对口腔鳞癌荷瘤裸鼠EGFR、C-Myc、p21表达的影响[J]. 上海口腔医学, 2023, 32(1): 40-46.
[4]	文旭涛, 马振, 张翀, 陶识丞, 陈兴金, 麦华明. 不同培养条件对CD133⁺原代口腔鳞癌细胞干性维持的影响[J]. 上海口腔医学, 2022, 31(4): 343-348.
[5]	秦志明, 揭伟萍, 池彦廷, 李宏锋, 李斌斌. 基于局部可变阈值的无监督定量Ki-67细胞增殖指数模型的初步建立[J]. 上海口腔医学, 2022, 31(3): 248-254.
[6]	买尔哈巴·买合木提, 拜婕, 如斯坦木·依米提, 姚志涛. 50例口腔鳞癌患者治疗过程中营养状况改变及影响因素分析[J]. 上海口腔医学, 2022, 31(2): 205-210.
[7]	谈亦然, 赵铜超, 琚梧桐, 钟来平. 长春新碱对口腔鳞癌中Stathmin调控作用的实验研究[J]. 上海口腔医学, 2022, 31(1): 1-5.
[8]	谢非, 秦星, 童桐, 蒋英英, 张建军. IGF2BP1在口腔鳞癌细胞耐药中的作用及机制探讨[J]. 上海口腔医学, 2021, 30(5): 456-461.
[9]	李蕾, 李晓东, 庄乾伟, 葛良玉, 李志萍, 顾倩平, 白玉婷, 孟箭. 超声热疗联合TPF化疗治疗19例老年晚期口腔鳞癌的疗效分析[J]. 上海口腔医学, 2021, 30(5): 543-547.
[10]	邵小钧, 朱乔, 刘有, 韩小东, 林小臻, 席庆. 咀嚼槟榔与口腔鳞癌的相关临床病理学因素分析[J]. 上海口腔医学, 2021, 30(3): 268-272.
[11]	薛佳艺, 朱晓燕, 危常磊, 孙培, 张慧, 邓婧. 25例口腔鳞癌患者唾液代谢组学分析[J]. 上海口腔医学, 2021, 30(2): 201-205.
[12]	王树斌, 秦帅华, 易雅群, 李新明. 216例口腔鳞癌患者术后心理困扰影响因素及放疗前、后生存质量评价[J]. 上海口腔医学, 2021, 30(1): 71-76.
[13]	傅宗云, 陶峰. MMP-14、ING4和HIF-1α在60例口腔鳞癌中的表达及临床意义[J]. 上海口腔医学, 2020, 29(6): 642-646.
[14]	王学梅, 蒋勇. 双硫仑对口腔鳞癌细胞上皮-间充质转化的影响及机制探讨[J]. 上海口腔医学, 2020, 29(2): 138-145.
[15]	刘族志, 赵永兴, 林建能, 周国平. 双氢青蒿素对人口腔鳞癌细胞KBV200多药耐药的影响[J]. 上海口腔医学, 2019, 28(6): 586-590.